Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy
Status:
Terminated
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Postoperative pain affects 80% of surgical patients and is one of the main negative symptoms
resulting from surgery. It impairs the recovery of patient since it is related to chronic
pain, nausea and vomiting and longer hospital stay, generating higher cost to the health
system. Thus, the use of new methods to control postoperative pain is recommended and
multimodal analgesia, an opioid-sparing strategies, has been widely used by several
researchers. Studies show that gabapentins have beneficial effects on postoperative pain
control when used as pre-anesthetic medication, also showing a reduction in opioid
consumption, with few adverse effects. Among gynecological surgeries, abdominal hysterectomy
is one of the procedures that generates the highest degree of acute postoperative pain. Thus,
the aim of the present study is to investigate the effect of oral pregabalin (300 mg) two
hours before abdominal hysterectomy procedures on postoperative pain. This study is a
randomized, double-blind, placebo controlled clinical trial. Patients submitted to abdominal
hysterectomy for benign pathologies will be selected and divided into two groups: the placebo
controlled group (P0) and the pregabalin 300 mg group (P1). Group P0 will receive a placebo
tablet one hour before the procedure, while group P1 will receive a 300 mg tablet of
pregabalin identical to the placebo tablet. The reduction of postoperative pain and the best
quality of patient recovery will be evaluated using the Visual Analogue Pain Scale (VAS) and
the McGill Pain Questionnaire. Also, it will be evaluated the consumption of opioids as a
rescue analgesic medication and the presence of adverse effects such as nausea and vomiting.